LUPIN

Mon, 10 Aug, 2026

• Filing

  Lupin announces FDA approval of Sodium Zirconium Cyclosilicate oral suspension in the United States

  NSE ↗
• Filing

  Lupin announces FDA approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States

  BSE ↗

Fri, 7 Aug, 2026

• News

  Lupin Q1 PAT rises 16% to Rs 1,417 crore

  m.economictimes.com ↗
• News

  Lupin Q1 results filed, driven by strong US sales

  cnbctv18.com ↗
• Filing

  Revised Q1 FY27 investor presentation filed under Regulation 30

  BSE ↗

Thu, 6 Aug, 2026

• FilingLupin Q1 FY2027 results announced, first quarterly earnings since the filing dateNSE ↗
• FilingLupin Limited files unaudited financial results for Q1 FY2026-27 (quarter ended 30 June 2026)NSE ↗
• Filing

  Lupin Q1 FY2027 results filed, first disclosure of quarterly audited earnings

  BSE ↗
• Filing

  Board approved unaudited Q1 FY27 standalone and consolidated financial results for quarter ended June 30, 2026

  BSE ↗
• Filing

  Q2 FY2026-27 unaudited results approved by board and filed

  BSE ↗

Tue, 4 Aug, 2026

• Filing

  Voting results and scrutinizer's report from the Forty-Fourth Annual General Meeting filed

  BSE ↗

Fri, 31 Jul, 2026

• Filing

  Press release notice filed

  NSE ↗
• Filing

  Lupin received FDA approval for Diazepam Injection, USP in the United States

  BSE ↗
• Filing

  Lupin announced U.S. FDA approval and launch of Sugammadex Injection under Regulation 30 press release

  BSE ↗

Wed, 22 Jul, 2026

• FilingBoard meeting scheduled for 06 Aug 2026 to consider and approve Q1 FY27 unaudited financial resultsBSE ↗

Tue, 21 Jul, 2026

• News

  Lupin spins out two cancer drug programmes into US-based Kaveri Therapeutics

  business-standard.com ↗
• News

  Lupin spins out two cancer drug programmes to new US venture, taking $1.6 million stake

  thehindubusinessline.com ↗
• News

  Lupin grants exclusive rights to Kaveri Therapeutics for two oncology programs

  business-standard.com ↗
• Filing

  Lupin's subsidiary acquired 332,000 common shares of Kaveri Therapeutics Inc. via licensing agreement

  NSE ↗
• FilingLupin Inc. U.S.A. acquired 332,000 common shares of Kaveri Therapeutics, Inc. U.S.A. via a licensing agreementBSE ↗